Shuchi Agrawal Singh

Dr Shuchi Agrawal-Singh is a senior postdoctoral fellow at the Cambridge Stem Cell Institute, studying deregulated epigenetic mechanisms in acute myeloid leukaemia (AML), with a focus on the impact of mutations and aberrantly expressed transcription factors such as HOXA9 in leukaemia maintenance.

Dr Agrawal-Singh received her PhD in Biology (Molecular Haematology/Oncology) from University of Muenster, Germany. Her work was amongst the earlier studies that defined the importance of DNA-promoter-hypermethylation in AML and to use it as potential MRD-biomarker for predicting relapse risk in AML patients. She received “magna cum laude plus” for her PhD (an outstanding PhD with 3 first author and 4 co-authored publications). She received an independent postdoctoral fellowship from Danish Research Council (FSS) and joined BRIC (Copenhagen University) for postdoctoral training. Her work at BRIC, demonstrated the dynamic role of Polycomb repressive complex (PRC2) in switching the lineage specific enhancer and transcriptional control during human-mesenchymal stem-cells differentiation towards osteoblasts.

Her research at CSCI she combines multiomics, functional genomics, proteomics and mechanistic validation to probe the molecular epigenetic mechanisms underlying the disease pathogenesis of AML. She is interested in investigating how mutations in epigenetic modulators impact on transcription, chromatin organisation and biomolecular condensation in leukaemogenesis, with the aim of implementing these discoveries for the development of novel epigenetic therapies. Dr Agrawal-Singh is the founder and co-organiser of the Cambridge Cancer Epigenetics Club (CCEC) virtual monthly seminar series.